

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory et. al.

Examiner: Dr. K. C. Carlson

Serial No.: 08/087,132

Art Unit: 1814

Filed: July 2, 1993

Docket: IG4-9.2(FWC)

For: NEW DIAGNOSTIC AND TREATMENT METHODS INVOLVING THE
CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR

Honorable Assistant Commissioner
of Patents
Washington, DC 20231

-- CERTIFICATE OF FACSIMILE TRANSMISSION --

I hereby certify that this correspondence is being
transmitted by facsimile to the Honorable Assistant
Commissioner of Patents, c/o Examiner Karen Carlson, Ph.D.,
Group 1800, Art Unit 1814, Washington, DC 20231,
at (703) 305-7401

Date:

4/15/96

By:

Elizabeth Lassen
Elizabeth LassenSUBMISSION OF REPLACEMENT COPY

S I R:

Applicants have been notified that their submission
herein entitled "Supplemental Reply under 37 CFR 1.111"
submitted by facsimile to Art Unit 1814 on April 2, 1996 has
somehow not reached the Examiner's desk.

Transmitted herewith are duplicate copies of the
following documents all bearing a date of April 2, 1996:
(1) facsimile confirmation record indicating successful
transmission of 14 pages;
(2) facsimile cover sheet;
(3) amendment transmittal cover sheet; and
(4) an 11 page amendment, with an extra sheet entitled
"Figure 14"

Respectfully submitted,

GENZYME CORPORATION

By:

Elizabeth Lassen
Elizabeth Lassen, Esquire
Reg. No. 31, 845
Attorney for Applicants

Dated: April 15, 1996
One Mountain Road
Framingham, MA 01701-9322
(508) 872-8400 X 2553

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory et al. Examiner: Dr. K. C. Carlson
 Serial No: 08/087,132 Art Unit: 1814
 Filed: July 2, 1993 Docket: IG 4-9.2(FWC)
 Title: New Diagnostic and Treatment Methods Involving the
 Cystic Fibrosis Transmembrane Regulator

The Honorable Commissioner of Patent and Trademarks
 Washington, DC 20231

-- CERTIFICATE OF FACSIMILE TRANSMISSION --

I hereby certify that this correspondence is being transmitted by facsimile to the Honorable Assistant Commissioner of Patents, c/o Examiner Karen Carlson, Ph.D., Group 1800, Art Unit 1814, Washington, DC 20231, at (703) 305-7401

Date: 4/2/96

By: Elizabeth Lassen
 Elizabeth Lassen

Dear Sir:

Transmitted herewith is an AMENDMENT in the above identified application.

1. The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA	RATE/LARGE ENTRY	FEE
TOTAL	22	MINUS	133	= 0	x 22	\$ 0
INDEP	4	MINUS	13	= 0	x 78	\$ 0
MULTIPLE DEPENDENT CLAIMS					x 250	0
TOTAL ADDITIONAL FEES						\$ 0

NO NEW MULTIPLE DEPENDENT CLAIMS ARE BEING ADDED

TOTAL \$ 0

2. The Commissioner is hereby authorized and requested to charge \$ 0 for the presentation of extra claims under 37 C.F.R. 1.16 and all patent processing fees under 37 C.F.R. 1.17, along with any additional fees under 37 C.F.R. 1.16 and 1.17, which may be required, or credit any overpayment, associated with this communication to Deposit Account No. 07-1074. A duplicate of this document is enclosed for this purpose.
3. Since the number of independent claims and the number of total claims that are now pending herein are substantially less than the numbers thereof that have been previously paid for, no fee is due in connection with this supplementary submission. However, the Patent Office is authorized to charge any fee that it determines is necessary in order to secure the filing of this Supplementary Reply and all enclosures.

Respectfully submitted,
 GENZYME CORPORATION

Elizabeth Lassen
 Elizabeth Lassen

Reg. No. 31,845

Attorney for Applicants

Dated: April 2, 1996